Cargando…

Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience

This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the application of managed entry agreements (MEAs) in European count...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciulla, Michele, Marinelli, Lisa, Di Biase, Giuseppe, Cacciatore, Ivana, Santoleri, Fiorenzo, Costantini, Alberto, Dimmito, Marilisa Pia, Di Stefano, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914690/ https://www.ncbi.nlm.nih.gov/pubmed/36767022 http://dx.doi.org/10.3390/healthcare11030447

Ejemplares similares

Wound-Healing Promotion and Anti-Inflammatory Properties of Carvacrol Prodrugs/Hyaluronic Acid Formulations
por: Marinelli, Lisa, et al.
Publicado: (2022)

Preparation, Characterization, and Biological Evaluation of a Hydrophilic Peptide Loaded on PEG-PLGA Nanoparticles
por: Marinelli, Lisa, et al.
Publicado: (2022)

Role of Dietary Supplements in the Management of Parkinson’s Disease
por: Ciulla, Michele, et al.
Publicado: (2019)

Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson’s Disease Agents
por: Di Stefano, Antonio, et al.
Publicado: (2019)

In Vitro Wound-Healing Properties of Water-Soluble Terpenoids Loaded on Halloysite Clay
por: Marinelli, Lisa, et al.
Publicado: (2021)

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018)

Synthesis and Biological Evaluation of Novel Cinnamic Acid-Based Antimicrobials
por: Mingoia, Marina, et al.
Publicado: (2022)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)

Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

Anti-Oxidant and Tyrosinase Inhibitory In Vitro Activity of Amino Acids and Small Peptides: New Hints for the Multifaceted Treatment of Neurologic and Metabolic Disfunctions
por: Luisi, Grazia, et al.
Publicado: (2018)

Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening
por: Poli, Giulio, et al.
Publicado: (2019)

Egypt, Europe sign Higher Education agreement
Publicado: (2006)

Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023)

Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan
por: DiBonaventura, Marco D, et al.
Publicado: (2019)

The digital flood: the diffusion of information technology across the U.S., Europe, and Asia
por: Cortada, James W
Publicado: (2012)

US signs agreement with European lab
Publicado: (1997)

On resin click-chemistry-mediated synthesis of novel enkephalin analogues with potent anti-nociceptive activity
por: Stefanucci, Azzurra, et al.
Publicado: (2019)

A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
por: Xoxi, Entela, et al.
Publicado: (2022)

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district
por: Polilli, Ennio, et al.
Publicado: (2016)

Across the pond–lessons from the US on integrated healthcare
por: Fleury, Marie-Josée, et al.
Publicado: (2009)

Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer’s Disease
por: Cacciatore, Ivana, et al.
Publicado: (2016)

Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer’s Disease
por: Turkez, Hasan, et al.
Publicado: (2021)

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022)

Stakeholder views of managed entry agreements: A literature review of national studies
por: Thanimalai, Subramaniam, et al.
Publicado: (2021)

Rimonabant-Based Compounds Bearing Hydrophobic Amino Acid Derivatives as Cannabinoid Receptor Subtype 1 Ligands
por: Dvorácskó, Szabolcs, et al.
Publicado: (2023)

Around the Tables – Contextual Factors in Healthcare Coverage Decisions Across Western Europe
por: Kleinhout-Vliek, Tineke, et al.
Publicado: (2020)

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
por: Efthymiadou, Olina, et al.
Publicado: (2022)

Activation of β- and γ-carbonic anhydrases from pathogenic bacteria with tripeptides
por: Stefanucci, Azzurra, et al.
Publicado: (2018)

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists
por: Szűcs, Edina, et al.
Publicado: (2020)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Storage power purchase agreements to enable the deployment of energy storage in Europe
por: Gabrielli, Paolo, et al.
Publicado: (2022)

Lockdowns across Europe
por: Le Page, Michael
Publicado: (2020)

Health economic value of an innovation: delimiting the scope and framework of future market entry agreements
por: Launois, Robert, et al.
Publicado: (2014)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Histidyl-Proline Diketopiperazine Isomers as Multipotent Anti-Alzheimer Drug Candidates
por: Turkez, Hasan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2i7v8g49n7go822r7vrns4k5vq